MedTrace Logo

Phamacokinetics and Safety Profiles of DA-5213 10mg in Healthy Subjects

NCT05106205 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-06-13

No results posted yet for this study

Summary

Phamacokinetics and safety profiles of DA-5213 10mg in Healthy subjects

Conditions

  • Healthy

Interventions

DRUG

DA-5213 10mg

single dose administration (one tablet once a day)

DRUG

DA-5213-R 10mg

single dose administration (one tablet once a day)

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-21
Primary Completion
2022-01-20
Completion
2022-01-20

Countries

  • South Korea

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05106205 on ClinicalTrials.gov